Hoy Wendy E
Centre for Chronic Disease, School of Medicine , The University of Queensland , Brisbane, Queensland 4029 , Australia.
Clin Kidney J. 2014 Dec;7(6):524-30. doi: 10.1093/ckj/sfu109. Epub 2014 Nov 13.
This article outlines the increasing awareness, service development and research in renal disease in Aboriginal people in Australia's Northern Territory, among whom the rates of renal replacement therapy (RRT) are among the highest in the world. Kidney failure and RRT dominate the intellectual landscape and consume the most professional energy, but the underlying kidney disease has recently swung into view, with increasing awareness of its connection to other chronic diseases and to health profiles and trajectories more broadly. Albuminuria is the marker of the underlying kidney disease and the best treatment target, and glomerulomegaly and focal glomerulosclerosis are the defining histologic features. Risk factors in its multideterminant genesis reflect nutritional and developmental disadvantage and inflammatory/infectious milieu, while the major putative genetic determinants still elude detection. A culture shift of "chronic disease prevention" has been catalyzed in part by the human pain, logistic problems and great costs associated with RRT. Nowadays chronic disease management is the central focus of indigenous primary care, with defined protocols for integrated testing and management of chronic diseases and with government reimbursed service items and free medicines for people in remote areas. Blood pressure, cardiovascular risk and chronic kidney disease (CKD) are all mitigated by good treatment, which centres on renin-angiotensin system blockade and good metabolic control. RRT incidence rates appear to be stabilizing in remote Aboriginal people, and chronic disease deaths rates are falling. However, the profound levels of disadvantage in many remote settings remain appalling, and there is still much to be done, mostly beyond the direct reach of health services.
本文概述了澳大利亚北领地原住民肾病方面日益提高的认识、服务发展及研究情况,在这些原住民中,肾脏替代治疗(RRT)的比例位居世界前列。肾衰竭和RRT在相关领域占据主导地位,并消耗了最多的专业精力,但潜在的肾脏疾病最近已进入视野,人们越来越意识到它与其他慢性疾病以及更广泛的健康状况和发展轨迹之间的联系。蛋白尿是潜在肾脏疾病的标志物和最佳治疗靶点,肾小球肿大和局灶性肾小球硬化是其典型的组织学特征。其多因素发病机制中的风险因素反映了营养和发育方面的劣势以及炎症/感染环境,而主要的假定基因决定因素仍未被发现。“慢性病预防”的观念转变在一定程度上是由RRT带来的人类痛苦、后勤问题和高昂成本所催化的。如今,慢性病管理是原住民初级保健的核心重点,有针对慢性病综合检测和管理的明确方案,偏远地区的人们可享受政府报销的服务项目和免费药物。良好的治疗可减轻血压、心血管风险和慢性肾脏病(CKD),治疗的核心是肾素 - 血管紧张素系统阻断和良好的代谢控制。在偏远的原住民中,RRT发病率似乎趋于稳定,慢性病死亡率也在下降。然而,许多偏远地区的严重劣势状况仍然令人震惊,仍有许多工作要做,而这些大多超出了卫生服务的直接覆盖范围。